# Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan

> **NCT01411423** · — · COMPLETED · sponsor: **Bayer** · enrollment: 3305 (actual)

## Conditions studied

- Carcinoma, Renal Cell

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT01411423
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04-18
- **Primary completion:** 2012-03-16
- **Final completion:** 2016-02-28
- **Target enrollment:** 3305 (ACTUAL)
- **Last updated:** 2018-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01411423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01411423, "Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01411423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*